The US National Institutes of Health (NIH) announced it continues to recommend anti-SARS-CoV-2 monoclonal antibodies that target the SARS-CoV-2 spike protein and block coronavirus entry into cells that have been evaluated for the treatment of COVID-19.
However, on April 8, 2021, the NIH confirmed changes to the monoclonal antibody cocktail recommendations.
Read More
